Search

Your search keyword '"Wainberg, Mark A."' showing total 1,116 results
Start Over Author "Wainberg, Mark A." Publication Type Academic Journals
1,116 results on '"Wainberg, Mark A."'

1. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

Author

Phillips, Andrew N, Cambiano, Valentina, Nakagawa, Fumiyo, Revill, Paul, Jordan, Michael R, Hallett, Timothy B, Doherty, Meg, De Luca, Andrea, Lundgren, Jens D, Mhangara, Mutsa, Apollo, Tsitsi, Mellors, John, Nichols, Brooke, Parikh, Urvi, Pillay, Deenan, de Wit, Tobias Rinke, Sigaloff, Kim, Havlir, Diane, Kuritzkes, Daniel R, Pozniak, Anton, van de Vijver, David, Vitoria, Marco, Wainberg, Mark A, Raizes, Elliot, Bertagnolio, Silvia, and Africa, Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Public Health, Health Sciences, Antimicrobial Resistance, HIV/AIDS, Infectious Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Africa South of the Sahara, Cost-Benefit Analysis, HIV Infections, HIV Integrase Inhibitors, Health Policy, Heterocyclic Compounds, 3-Ring, Humans, Middle Aged, Models, Economic, Oxazines, Piperazines, Pyridones, Treatment Outcome, Young Adult, Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThere is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness and cost-effectiveness of alternative public health responses in countries in sub-Saharan Africa where the prevalence of pretreatment drug resistance to NNRTIs is high.MethodsThe HIV Synthesis Model is an individual-based simulation model of sexual HIV transmission, progression, and the effect of ART in adults, which is based on extensive published data sources and considers specific drugs and resistance mutations. We used this model to generate multiple setting scenarios mimicking those in sub-Saharan Africa and considered the prevalence of pretreatment NNRTI drug resistance in 2017. We then compared effectiveness and cost-effectiveness of alternative policy options. We took a 20 year time horizon, used a cost effectiveness threshold of US$500 per DALY averted, and discounted DALYs and costs at 3% per year.FindingsA transition to use of a dolutegravir as a first-line regimen in all new ART initiators is the option predicted to produce the most health benefits, resulting in a reduction of about 1 death per year per 100 people on ART over the next 20 years in a situation in which more than 10% of ART initiators have NNRTI resistance. The negative effect on population health of postponing the transition to dolutegravir increases substantially with higher prevalence of HIV drug resistance to NNRTI in ART initiators. Because of the reduced risk of resistance acquisition with dolutegravir-based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this policy option is also predicted to lead to a reduction of overall programme cost.InterpretationA future transition from first-line regimens containing efavirenz to regimens containing dolutegravir formulations in adult ART initiators is predicted to be effective and cost-effective in low-income settings in sub-Saharan Africa at any prevalence of pre-ART NNRTI resistance. The urgency of the transition will depend largely on the country-specific prevalence of NNRTI resistance.FundingBill & Melinda Gates Foundation, World Health Organization.

Published
2018

2. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial

Author

Aboulker, Jean-Pierre, Bajos, Nathalie, Baril, Jean-Guy, Besnier, Michel, Binesse, Johan, Carette, Diane, Cattin, Grégoire, Chéret, Antoine, Chidiac, Christian, Choucair, Elias, Delfraissy, Jean-François, Demoulin, Baptiste, Diallo, Alpha, Durant-Zaleski, Isabelle, Doré, Véronique, Etien, Nicolas, Euphrasie, Françoise, Fonsart, Julien, Foubert, Valérie, Gibowski, Séverine, Girard, Gabriel, Guillon, Brigitte, Le Mestre, Soizic, Lert, France, Leturque, Nicolas, Lorente, Nicolas, Mennecier, Anaïs, Morin, Michel, Netzer, Emmanuelle, Otis, Joanne, Pasquet, Armelle, Peytavin, Gilles, Pialoux, Gilles, Préau, Marie, Rabian, Cécile, Rozenbaum, Willy, Sagaon-Teyssier, Luis, Saïdi, Yacine, Saouzanet, Marine, Simon, Marie-Christine, Suzan-Monti, Marie, Thompson, David, Timsit, Julie, Trottier, Benoît, Wainberg, Mark, Antoni, Guillemette, Tremblay, Cécile, Delaugerre, Constance, Charreau, Isabelle, Cua, Eric, Rojas Castro, Daniela, Raffi, François, Chas, Julie, Huleux, Thomas, Spire, Bruno, Capitant, Catherine, Cotte, Laurent, Meyer, Laurence, and Molina, Jean-Michel

Published
2020
Full Text
View/download PDF

3. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Author

Rhee, Soo-Yon, Jordan, Michael R, Raizes, Elliot, Chua, Arlene, Parkin, Neil, Kantor, Rami, Van Zyl, Gert U, Mukui, Irene, Hosseinipour, Mina C, Frenkel, Lisa M, Ndembi, Nicaise, Hamers, Raph L, Rinke de Wit, Tobias F, Wallis, Carole L, Gupta, Ravindra K, Fokam, Joseph, Zeh, Clement, Schapiro, Jonathan M, Carmona, Sergio, Katzenstein, David, Tang, Michele, Aghokeng, Avelin F, De Oliveira, Tulio, Wensing, Annemarie MJ, Gallant, Joel E, Wainberg, Mark A, Richman, Douglas D, Fitzgibbon, Joseph E, Schito, Marco, Bertagnolio, Silvia, Yang, Chunfu, and Shafer, Robert W

Subjects
Humans, HIV-1, HIV Infections, Ritonavir, Reverse Transcriptase Inhibitors, Protease Inhibitors, Treatment Failure, Drug Therapy, Combination, Drug Resistance, Viral, Mutation, Point-of-Care Systems, Lopinavir, Genotyping Techniques, Darunavir, Atazanavir Sulfate, Drug Therapy, Combination, Drug Resistance, Viral, General Science & Technology, MD Multidisciplinary
Abstract

The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) hardest hit by the HIV-1 pandemic. Genotypic drug resistance testing could facilitate the choice of initial ART in areas with rising transmitted drug resistance (TDR) and enable care-providers to determine which individuals with virological failure (VF) on a first- or second-line ART regimen require a change in treatment. An inexpensive near point-of-care (POC) genotypic resistance test would be useful in settings where the resources, capacity, and infrastructure to perform standard genotypic drug resistance testing are limited. Such a test would be particularly useful in conjunction with the POC HIV-1 viral load tests that are currently being introduced in LMICs. A POC genotypic resistance test is likely to involve the use of allele-specific point mutation assays for detecting drug-resistance mutations (DRMs). This study proposes that two major nucleoside reverse transcriptase inhibitor (NRTI)-associated DRMs (M184V and K65R) and four major NNRTI-associated DRMs (K103N, Y181C, G190A, and V106M) would be the most useful for POC genotypic resistance testing in LMIC settings. One or more of these six DRMs was present in 61.2% of analyzed virus sequences from ART-naïve individuals with intermediate or high-level TDR and 98.8% of analyzed virus sequences from individuals on a first-line NRTI/NNRTI-containing regimen with intermediate or high-level acquired drug resistance. The detection of one or more of these DRMs in an ART-naïve individual or in a individual with VF on a first-line NRTI/NNRTI-containing regimen may be considered an indication for a protease inhibitor (PI)-containing regimen or closer virological monitoring based on cost-effectiveness or country policy.

Published
2015

4. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

Author

Heredia, Alonso, Davis, Charles, Amin, Mohammed N, Le, Nhut M, Wainberg, Mark A, Oliveira, Maureen, Deeks, Steven G, Wang, Lai-Xi, and Redfield, Robert R

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, HIV/AIDS, Genetics, Complementary and Integrative Health, Sexually Transmitted Infections, Infection, Anti-HIV Agents, Cells, Cultured, Deoxycytidine, Drug Resistance, Viral, Emtricitabine, Enzyme-Linked Immunosorbent Assay, HIV Core Protein p24, HIV Reverse Transcriptase, HIV-1, Humans, Lymphocytes, Mutation, Missense, Real-Time Polymerase Chain Reaction, Resveratrol, Stilbenes, Virus Replication, antiretroviral therapy, cytosine analogs, drug resistance, emtricitabine, M184V mutation, nucleoside analog reverse transcriptase inhibitors, resource-limited setting, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveThe M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhibitors lamivudine and emtricitabine. The reverse transcriptase enzyme of M184V HIV-1 mutants has reduced processivity, resulting in reduced viral replication, particularly at low deoxynucleotide (dNTP) levels. We hypothesized that lowering intracellular dNTPs with resveratrol, a dietary supplement, could interfere with replication of M184V HIV-1 mutants.Design and methodsEvaluation of the activity of resveratrol on infection of primary peripheral blood lymphocytes by wild-type and M184V mutant HIV-1. We assayed both molecular clones and primary isolates of HIV-1, containing M184V alone and in combination with other reverse transcriptase mutations. Viral infection was quantified by p24 ELISA and by quantitative real-time PCR analysis. Cell viability was measured by colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assays.ResultsIn virus-infectivity assays, resveratrol did not inhibit replication of wild-type NL4-3 (resveratrol EC50 > 10 μmol/l), but it inhibited NL4-3 184V mutant (resveratrol EC50 = 5.8 μmol/l). These results were confirmed by real-time PCR analysis of early and late products of reverse transcription. Resveratrol inhibited molecular clones and primary isolates carrying M184V, alone or in combination with other reverse transcriptase mutations (resveratrol EC50 values ranging from 2.5 to 7.7 μmol/l).ConclusionsResveratrol inhibits HIV-1 strains carrying the M184V mutation in reverse transcriptase. We propose resveratrol as a potential adjuvant in HIV-1 therapy, particularly in resource-limited settings, to help control emtricitabine-resistant M184V HIV-1 mutants.

Published
2014

9. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

Author

Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P, Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon-Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C, Diallo, A, Gibowski, S, Delfraissy, J F, Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Molina, Jean-Michel, Wainberg, Mark A, Trottier, Benoit, Tremblay, Cécile, Baril, Jean-Guy, Pialoux, Gilles, Cotte, Laurent, Chéret, Antoine, Pasquet, Armelle, Cua, Eric, Besnier, Michel, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand-Zaleski, Isabelle, Meyer, Laurence, Aboulker, Jean-Pierre, Spire, Bruno, Suzan-Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Capitant, Catherine, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie-Christine, Charreau, Isabelle, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, Rabian, Cecile, Chas, Julie, Tremblay, Cecile, Rojas-Castro, Daniela, Bernaud, Camille, Pintado, Claire, Sagaon-Teyssier, Luis, Mestre, Soizic Le, Ponscarme, Diane, and Doré, Veronique

Published
2017
Full Text
View/download PDF

12. Reverse Transcriptase Fidelity and HIV-1 Variation

Author

Preston, Bradley D., Keulen, Wilco, Nijhuis, Monique, Schuurman, Rob, Berkhout, Ben, Boucher, Charles, Balzarini, Jan, Pelemans, Heidi, De Clercq, Erik, Karlsson, Anna, Kleim, Jörg-Peter, Prasad, Vinayaka R., Drosopoulos, William C., and Wainberg, Mark A.

Published
1997

19. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis

Author

Liegeon, Geoffroy, Antoni, Guillemette, Pialoux, Gilles, Capitant, Catherine, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cécile, Cua, Eric, Senneville, Eric, Raffi, François, Meyer, Laurence, Molina, Jean?Michel, Meyer, L, Capitant, C, Charreau, I, Netzer, E, Leturque, N, Binesse, J, Foubert, V, Saouzanet, M, Euphrasie, F, Carette, D, Guillon, B, Saïdi, Y, Aboulker, J P., Spire, B, Suzan, M, Cattin, G, Demoulin, B, Sagaon?Teyssier, L, Lorente, N, Doré, V, Choucair, E, Le Mestre, S, Mennecier, A, Etien, N, Simon, M C., Diallo, A, Gibowski, S, Delfraissy, J F., Thompson, D, Sas, J, Pankovitch, J, Klein, M, Anis, A, Wainberg, Mark A., Trottier, Benoit, Baril, Jean?Guy, Chéret, Antoine, Pasquet, Armelle, Hall, Nolwenn, Rozenbaum, Willy, Chidiac, Christian, Delaugerre, Constance, Bajos, Nathalie, Timsit, Julie, Peytavin, Gilles, Fonsart, Julien, Durand?Zaleski, Isabelle, Aboulker, Jean?Pierre, Spire, Bruno, Suzan?Monti, Marie, Girard, Gabriel, Castro, Daniela Rojas, Préau, Marie, Morin, Michel, Thompson, David, Mennecier, Anaïs, Choucair, Elias, Doré, Véronique, Simon, Marie?Christine, Otis, Joanne, Lert, France, Diallo, Alpha, Gibowski, Séverine, and Rabian, Cecile

Subjects
MSM (Men who have sex with men) -- Health aspects, Tenofovir -- Patient outcomes, Glomerular filtration rate -- Testing, Emtricitabine -- Patient outcomes, HIV infection -- Prevention, Health
Abstract

: Introduction: Daily pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) is associated with a small but statistically significant decrease in estimated glomerular filtration rate (eGFR). We assessed the renal safety of on‐demand PrEP with TDF/FTC in HIV‐1 uninfected men. Methods: We used data from the randomized double‐blind placebo‐controlled ANRS‐IPERGAY trial and its open‐label extension conducted between February 2012 and June 2016 among HIV‐uninfected MSM starting on‐demand PrEP. Using linear mixed model, we evaluated the mean eGFR decline from baseline over time and determined risks factors associated with eGFR decline during the study. Results: During the blind phase, with a median follow‐up of 9.4 months, the mean decline slope of eGFR from baseline was −0.88 and −1.53 mL/min/1.73 m[sup.2] per year in the placebo (n = 201) and the TDF/FTC group (n = 198) respectively, with a slope difference of 0.65 mL/min/1.73 m[sup.2] per year (p = 0.27). Including both phases, 389 participants started on‐demand TDF/FTC with a median follow‐up of 19.2 months and a mean decline of eGFR from baseline of −1.14 mL/min/1.73 m[sup.2] per year (p < 0.001). The slope of eGFR reduction was not significantly different in participants with baseline eGFR ≤ 90 mL/min/1.73 m[sup.2] (p = 0.44), age >40 years (p = 0.24) or hypertension (p = 0.21). There was a dose‐response relationship between recent tenofovir exposure and lower eGFR when considering the number of pills taken in the two months prior the visit (eGFR difference of −0.88 mL/min/1.73 m[sup.2] between >15 pills/month vs. ≤15 pills/month, p < 0.01) or plasma tenofovir concentrations at the visit (eGFR difference compared to ≤2 ng/mL: >2 to ≤10ng/mL: −0.98 mL/min/1.73 m[sup.2], >10 to ≤40ng/mL: −1.28 mL/min/1.73 m[sup.2], >40 ng/mL: −1.82 mL/min/1.73 m[sup.2], p < 0.001). Three participants discontinued TDF/FTC for eGFR < 60 mL/min/1.73 m[sup.2] during the OLE phase. No case of Fanconi syndrome was reported. Conclusions: The renal safety of on‐demand PrEP with TDF/FTC was good. The overall reduction and intermittent exposure to TDF/FTC may explain this good renal safety., Introduction Pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) – emtricitabine (FTC) raises a lot of expectations to hamper HIV epidemic due to its high effectiveness to prevent HIV acquisition [...]

Published
2020
Full Text
View/download PDF

26. A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

Author

Patterson, S, Jose, S, Samji, H, Cescon, A, Ding, E, Zhu, J, Anderson, J, Burchell, AN, Cooper, C, Hill, T, Hull, M, Klein, MB, Loutfy, M, Martin, F, Machouf, N, Montaner, JSG, Nelson, M, Raboud, J, Rourke, SB, Tsoukas, C, Hogg, RS, Sabin, C, Kelly, Deborah, Sanche, Stephen, Wong, Alexander, Antoniou, Tony, Bayoumi, Ahmed, Nosyk, Bohdan, Cotterchio, Michelle, Goldsmith, Charlie, Guillemi, Silvia, Richard Harrigan, P., Harris, Marianne, Hosein, Sean, Johnston, Sharon, Liddy, Clare, Lima, Viviane, Moore, David, Palmer, Alexis, Phillips, Peter, Rachlis, Anita, Smieja, Marek, Trottier, Benoit, Wainberg, Mark, Walmsley, Sharon, Archibald, Chris, Clement, Ken, Doolittle‐Romas, Monique, Edmiston, Laurie, Huskins, Brian, Lawless, Jerry, Lee, Douglas, Masching, Renee, Tattle, Stephen, Zahirieh, Alireza, Allen, Claire, Calvez, Stryker, Colley, Guillaume, Chia, Jason, Corsi, Daniel, Gilbert, Louise, Gataric, Nada, Leslie, Alia, Light, Lucia, Mackie, David, Pexos, Costa, Shurgold, Susan, Szadkowski, Leah, Wong, John, Yip, Benita, Younger, Jaime, Ainsworth, Jonathan, Allan, Sris, Babiker, Abdel, Chadwick, David, Delpech, Valerie, Dunn, David, Fisher, Martin, Gazzard, Brian, Gilson, Richard, Gompels, Mark, Hay, Phillip, Johnson, Margaret, Kegg, Stephen, Leen, Clifford, Orkin, Chloe, Palfreeman, Adrian, Phillips, Andrew, Pillay, Deenan, Post, Frank, Pritchard, Jillian, Sachikonye, Memory, Schwenk, Achim, Tariq, Anjum, Walsh, John, Thornton, Alicia, Glabay, Adam, Perry, Nicky, Tilbury, Stuart, Youssef, Elaney, Churchill, Duncan, Everett, Rhiannon, Asboe, David, Mandalia, Sundhiya, Korat, Hardik, Taylor, Chris, Gleisner, Zachary, Ibrahim, Fowzia, Campbell, Lucy, Brima, Nataliya, Williams, Ian, Youle, Mike, Lampe, Fiona, Smith, Colette, Tsintas, Rob, Chaloner, Clinton, Hutchinson, Samantha, Huntington, Susie, Mackie, Nicky, Winston, Alan, Weber, Jonathan, Ramzan, Farhan, Carder, Mark, Lynch, Janet, Hand, James, de Souza, Carl, Munshi, Sajid, Miller, Sheila, Wood, Chris, Wilson, Alan, Morris, Sheila, Allan, Sue, Memon, Khurram, Lewszuk, Adam, Cope, Emma, Gibson, Jane, Main, Paul, Dhillon, Mandip, Russell‐Sharpe, Sarah, Harte, Andrew, Clay, Stephen, Spencer, Hazel, Jones, Ron, Cumming, Shirley, Atkinson, Claire, and Trevelion, Roy

Published
2017
Full Text
View/download PDF

31. Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy

Author

Kesselring, S, Cescon, A, Colley, G, Osborne, C, Zhang, W, Raboud, JM, Hosein, SR, Burchell, AN, Cooper, C, Klein, MB, Loutfy, M, Machouf, N, Montaner, JSG, Rachlis, A, Tsoukas, C, Hogg, RS, Lima, VD, Hogg, Robert, Kelly, Deborah, Sanche, Stephen, Wong, Alexander, Antoniou, Tony, Bayoumi, Ahmed, Hull, Mark, Nosyk, Bohdan, Cotterchio, Michelle, Goldsmith, Charlie, Guillemi, Silvia, Harrigan, P. Richard, Harris, Marianne, Johnston, Sharon, Kendall, Claire, Liddy, Clare, Marsh, David, Moore, David, Palmer, Alexis, Patterson, Sophie, Phillips, Peter, Rachlis, Anita, Rourke, Sean B., Samji, Hasina, Smieja, Marek, Trottier, Benoit, Wainberg, Mark, Walmsley, Sharon, Archibald, Chris, Clement, Ken, Crouzat, Fred, DoolittleRomas, Monique, Edmiston, Laurie, Gardner, Sandra, Huskins, Brian, Lee, Douglas, Masching, Renee, Tattle, Stephen, Zahirieh, Alireza, Calvez, Stryker, Chia, Jason, Corsi, Daniel, Gilbert, Louise, Gataric, Nada, Light, Lucia, Mackie, David, Merritt, Katelyn, Pexos, Costas, Shurgold, Susan, Szadkowski, Leah, Galanakis, Chrissi, Sandler, Ina, Yip, Benita, Younger, Jaime, and Zhu, Julia

Published
2017
Full Text
View/download PDF

32. Biochemical Mechanism of HIV-1 Resistance to Rilpivirine

Author

Singh, Kamalendra, Marchand, Bruno, Rai, Devendra K., Sharma, Bechan, Michailidis, Eleftherios, Ryan, Emily M., Matzek, Kayla B., Leslie, Maxwell D., Hagedorn, Ariel N., Li, Zhe, Norden, Pieter R., Hachiya, Atsuko, Parniak, Michael A., Xu, Hong-Tao, Wainberg, Mark A., and Sarafianos, Stefan G.

Published
2012
Full Text
View/download PDF

38. Whither or Wither Microbicides?

Author

Grant, Robert M., Hamer, Dean, Hope, Thomas, Johnston, Rowena, Lange, Joep, Lederman, Michael M., Lieberman, Judy, Miller, Christopher J., Moore, John P., Mosier, Donald E., Richman, Douglas D., Schooley, Robert T., Springer, Marty S., Veazey, Ronald S., and Wainberg, Mark A.

Published
2008

46. A Plea for Justice for Jailed Medical Workers

Author

Ahuja, Sunil K., Aiuti, Fernando, Berkhout, Ben, Biberfeld, Peter, Burton, Dennis R., Colizzi, Vittorio, Deeks, Steven G., Desrosiers, Ronald C., Dierich, Manfred P., Doms, Robert W., Emerman, Michael, Gallo, Robert C., Girard, Marc, Greene, Warner C., Hoxie, James A., Hunter, Eric, Klein, George, Korber, Bette, Kuritzkes, Daniel R., Lederman, Michael M., Malim, Michael H., Marx, Preston A., McCune, Joseph M., McMichael, Andrew, Miller, Christopher, Miller, Veronica, Montagnier, Luc, Montefiori, David C., Moore, John P., Nixon, Douglas F., Overbaugh, Julie, Pauza, C. David, Richman, Douglas D., Saag, Michael S., Sattentau, Quentin, Schooley, Robert T., Shattock, Robin, Shaw, George M., Stevenson, Mario, Trkola, Alexandra, Wainberg, Mark A., Weiss, Robin A., Wolinsky, Steven, and Zack, Jerome A.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results